Grant: Collaborative Health Research Projects
Université Laval
$72,150.00
Identification and validation of new therapeutic targets for autoimmune diseases
EF 2011-12
Résumé
Autoimmune diseases such as rheumatoid arthritis and inflammatory bowel diseases (IBD) affect more than
one million Canadians. Most autoimmune diseases are the results of misdirected inflammation. Sadly, while
the overall mortality rates in the general population has declined substantially over the last decade, patients
with autoimmune diseases have not experienced the same improvements in survival. In addition, aging of
population contributes to the increase of autoimmune disease cases monitored every year in North America. A
better control of chronic inflammation is therefore urgently needed to improve the quality of life of these
patients.
The pathogenesis of these disorders is not well understood. However, several cytokines have been identified as
important players in inflammatory diseases. Indeed, anti-cytokine therapeutic agents have had a profound effect
on the treatment of patients with arthritis and IBD. However, 40% of patients with Crohn disease or arthritis,
and most with ulcerative colitis do not respond to anti-TNF therapy. Attention has been focused on the well
known cytokines to now, but few studies have examined the role of alarmins in these diseases. Alarmins are
small intracellular proteins released upon cell necrosis or activation which exhibit cytokine-like activities when
released in the extracellular milieu. Examples of alarmins include the High Mobility Group Box-1 and
S100A8/A9 proteins. Increasing evidences point toward a pivotal role for alarmins in chronic inflammation
and autoimmune diseases in general.
In this proposal, we propose to confirm the important role of alarmins in auto immune diseases using two
animal models for rheumatoid arthritis and IBD. In brief, we will:
1) Identify new therapeutic targets for the control of chronic inflammation by a combination of proteomic and
genomic approaches. We intend to determine cytokine and alarmin release in mouse models of arthritis
(collagen-induced arthritis) and inflammatory bowel diseases (TNBS and oxazolone models). DNA chips will
allow following cytokine expression at the inflammatory site, while 2D gels, LC-MS/MS and multiplex
analyses of serum and tissue samples will determine cytokine and alarmin secretion.
2) Validate the therapeutic targets by examining the effect of candidate neutralizing drugs in the same models.
We will identify high affinity peptides binding specifically to the targets identify in the previous section.
Because peptides are usually unstable in vivo, we will fused them to the nucleocapsid (NC) of a plant virus
(PapMV; papaya mosaic virus) platform to improve its stability. Furthermore, PapMV NC self-assembles into
a 20mer disk upon expression in bacteria from which it can be easily purified. The multimerization of the
peptide on this platform is likely to improve the avidity of the complex for their target and increase the
neutralizing property of the fusion protein as compared to the use of the unstable synthetic peptide.
Alternatively, the peptides will be added to the protein cauliflower mosaic virus (CaMV) pIII, which
spontaneously forms tetramers. Both proteins have been selected because they have been studied extensively in
Dr Leclerc's laboratory, are highly stable, easy to purify in large quantities, resistant to proteases and
non-immunogenic in mouse. Efficacy of the immunotherapy drugs will then be tested in the same mouse
models of arthritis and inflammatory bowel disease.
This research project is a unique collaboration between a researcher investigating autoimmune diseases and a
specialist on protein engineering and viral assembly. Together, we have solid experience of mouse models of
autoimmune diseases and protein engineering and have access to state-of-the-art genomic and proteomic
facilities. A successful outcome will uncover much needed new potential targets for pharmacologic or biologic
intervention and further extend our knowledge of the pathogenesis of autoimmune diseases.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
365369-2009
Name nom
Tessier, Philippe
Department département
Microbiologie-infectiologie et d'immunologie
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2009
Award amount
72150
Program id
CHRPJ
Program nane en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
3
Nb partie
3
Application title
Identification and validation of new therapeutic targets for autoimmune diseases
Keyword
NSERC
Application summary
Autoimmune diseases such as rheumatoid arthritis and inflammatory bowel diseases (IBD) affect more than
one million Canadians. Most autoimmune diseases are the results of misdirected inflammation. Sadly, while
the overall mortality rates in the general population has declined substantially over the last decade, patients
with autoimmune diseases have not experienced the same improvements in survival. In addition, aging of
population contributes to the increase of autoimmune disease cases monitored every year in North America. A
better control of chronic inflammation is therefore urgently needed to improve the quality of life of these
patients.
The pathogenesis of these disorders is not well understood. However, several cytokines have been identified as
important players in inflammatory diseases. Indeed, anti-cytokine therapeutic agents have had a profound effect
on the treatment of patients with arthritis and IBD. However, 40% of patients with Crohn disease or arthritis,
and most with ulcerative colitis do not respond to anti-TNF therapy. Attention has been focused on the well
known cytokines to now, but few studies have examined the role of alarmins in these diseases. Alarmins are
small intracellular proteins released upon cell necrosis or activation which exhibit cytokine-like activities when
released in the extracellular milieu. Examples of alarmins include the High Mobility Group Box-1 and
S100A8/A9 proteins. Increasing evidences point toward a pivotal role for alarmins in chronic inflammation
and autoimmune diseases in general.
In this proposal, we propose to confirm the important role of alarmins in auto immune diseases using two
animal models for rheumatoid arthritis and IBD. In brief, we will:
1) Identify new therapeutic targets for the control of chronic inflammation by a combination of proteomic and
genomic approaches. We intend to determine cytokine and alarmin release in mouse models of arthritis
(collagen-induced arthritis) and inflammatory bowel diseases (TNBS and oxazolone models). DNA chips will
allow following cytokine expression at the inflammatory site, while 2D gels, LC-MS/MS and multiplex
analyses of serum and tissue samples will determine cytokine and alarmin secretion.
2) Validate the therapeutic targets by examining the effect of candidate neutralizing drugs in the same models.
We will identify high affinity peptides binding specifically to the targets identify in the previous section.
Because peptides are usually unstable in vivo, we will fused them to the nucleocapsid (NC) of a plant virus
(PapMV; papaya mosaic virus) platform to improve its stability. Furthermore, PapMV NC self-assembles into
a 20mer disk upon expression in bacteria from which it can be easily purified. The multimerization of the
peptide on this platform is likely to improve the avidity of the complex for their target and increase the
neutralizing property of the fusion protein as compared to the use of the unstable synthetic peptide.
Alternatively, the peptides will be added to the protein cauliflower mosaic virus (CaMV) pIII, which
spontaneously forms tetramers. Both proteins have been selected because they have been studied extensively in
Dr Leclerc's laboratory, are highly stable, easy to purify in large quantities, resistant to proteases and
non-immunogenic in mouse. Efficacy of the immunotherapy drugs will then be tested in the same mouse
models of arthritis and inflammatory bowel disease.
This research project is a unique collaboration between a researcher investigating autoimmune diseases and a
specialist on protein engineering and viral assembly. Together, we have solid experience of mouse models of
autoimmune diseases and protein engineering and have access to state-of-the-art genomic and proteomic
facilities. A successful outcome will uncover much needed new potential targets for pharmacologic or biologic
intervention and further extend our knowledge of the pathogenesis of autoimmune diseases.